Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Cellebrite DI (CLBT) over the last 6 years, with Q4 2025 value amounting to $124.5 million.

  • Cellebrite DI's Cash & Equivalents fell 3432.94% to $124.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $124.5 million, marking a year-over-year decrease of 3432.94%. This contributed to the annual value of $124.5 million for FY2025, which is 3432.94% down from last year.
  • Latest data reveals that Cellebrite DI reported Cash & Equivalents of $124.5 million as of Q4 2025, which was down 3432.94% from $191.7 million recorded in Q3 2025.
  • In the past 5 years, Cellebrite DI's Cash & Equivalents registered a high of $191.7 million during Q1 2025, and its lowest value of $87.6 million during Q4 2022.
  • For the 5-year period, Cellebrite DI's Cash & Equivalents averaged around $141.3 million, with its median value being $135.1 million (2021).
  • In the last 5 years, Cellebrite DI's Cash & Equivalents tumbled by 3995.81% in 2022 and then soared by 11623.25% in 2023.
  • Cellebrite DI's Cash & Equivalents (Quarter) stood at $146.0 million in 2021, then crashed by 39.96% to $87.6 million in 2022, then surged by 116.23% to $189.5 million in 2023, then changed by 0.0% to $189.5 million in 2024, then plummeted by 34.33% to $124.5 million in 2025.
  • Its Cash & Equivalents was $124.5 million in Q4 2025, compared to $191.7 million in Q3 2025 and $191.7 million in Q2 2025.